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Abstract
Rationale Evidence has implicated the endogenous opioids, in
particular μ-opioid receptors, in emotional behavior and regula-
tion of reward circuits, especially in the context of heroin addic-
tion and hedonic responses to ingestive rewards. The μ-opioid
receptor antagonist naltrexone (NTX) has been reported to be
effective in preventing relapse to alcoholism and in reducing
alcohol and cocaine craving during abstinence.
Objectives The aim of the present experiments was to inves-
tigate the effects of a novel selective μ-opioid receptor antag-
onist GSK1521498 on cocaine and heroin seeking and the
primary reinforcement of drug self-administration behavior.
Methods Rats were first trained to self-administer cocaine or
heroin and then to seek the drugs over prolonged periods of time
under a second-order schedule of reinforcement, in which
responding is maintained by contingent presentation of a drug-
associated conditioned reinforcer. On a stable baseline, animals
were treated with either GSK1521498 (0.1, 1, 3 mg/kg; IP) or
NTX (0.1, 1, 3 mg/kg; SC) before each test session.
Results Cocaine seeking was dose-dependently decreased
following GSK1521498 treatment. However, the same treat-
ment had no effect on cocaine self-administration under a
continuous reinforcement schedule. Treatment with NTX
had a less pronounced but similar effect. GSK1521498,
but not NTX, dose-dependently reduced heroin seeking both
before and after infusion of the drug although both increased
heroin self-administration under continuous reinforcement.
Conclusions These data suggest that GSK1521498, by re-
ducing opioid receptor signaling at the μ-opioid receptor,
may have therapeutic potential to reduce the propensity to
seek cocaine or heroin and, additionally, to diminish the
consequence of an initial relapse to heroin taking.
Keywords Addiction . Cocaine seeking . Heroin seeking .
Conditioned stimulus . Naltrexone . μ-opioid receptor
antagonist
Introduction
A fundamental feature of addiction to drugs is the propensity
to relapse to drug use after short or even prolonged periods of
abstinence. Drug-associated environmental stimuli that trigger
craving, drug seeking, and relapse are critical factors and
provide targets for treatments designed to prevent the tenden-
cy to relapse and thereby promote abstinence.
Opioid neurotransmission is implicated in responding and
adaptation to emotionally salient stimuli in both animals and
humans (Zubieta et al. 2003; Moles et al. 2004). Transmission
via μ-opioid receptors mediates an important component of
the primary reinforcing effects of opiates such as heroin
(Ettenberg et al. 1982) and is also implicated in alcohol (Lê
et al. 1999), but not stimulant, drug reinforcement mecha-
nisms (Ettenberg et al. 1982). Activation of the opioid system
may also play a role inmediating conditioned incentive effects
of stimuli associated with drugs of abuse (Zubieta et al. 2005).
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In animal studies, opioid receptor antagonists (such as nal-
trexone and naloxone) have been shown to reduce cue-elicited
reinstatement after extinction of heroin- (Shaham and Stewart
1996), methamphetamine- (Anggadiredja et al. 2004),
nicotine- (Liu et al. 2009), ethanol- (Burattini et al. 2006),
and cocaine-seeking behavior (Burattini et al. 2008), as well
as to reduce alcohol preference in alcohol-dependent rats
(Marfaing-Jallat et al. 1983) and drinking in rats selectively
bred for high-alcohol preference (Froehlich et al. 1990).
Naltrexone has also been reported to reduce rates of relapse
to heavy drinking (Volpicelli et al. 1995), providing the basis
for approval by the Food and Drug Administration of its use
for the treatment of alcohol and opioid dependence.
In the present study, we investigated the effects of
GSK1521498, a novel selective μ-opioid receptor antago-
nist in clinical development for behavioral and drug addic-
tive disorders (Nathan et al. 2011, 2012), in comparison to
naltrexone (NTX), on cocaine- and heroin-seeking behavior
measured under a second-order schedule of reinforcement,
in which prolonged periods of drug-seeking behavior are
maintained by contingent presentation of a drug-associated
conditioned reinforcer. This procedure allows the effects of
the compounds on drug seeking to be measured both before
and after cocaine or heroin have been self-administered. We
have also assessed the effects of the two compounds on the
reinforcing effects of cocaine and heroin in rats self-
administering the drugs under a continuous reinforcement
schedule. GSK1521498 has been reported to act more se-
lectively than NTX as an antagonist of exogenous agonist
activation at the μ-opioid receptor and, under conditions of
high receptor expression and endogenous receptor activa-
tion in cellular assays, to have inverse agonist properties,
thereby reducing receptor activation in the absence of an
exogenous agonist. By contrast, NTX has been reported to
have partial agonist activity (about 20 % of maximum
agonist activity) at μ-opioid receptors (Ignar et al. 2011;
Rabiner et al. 2011).
The results of the present study show that reducing
opioid receptor signaling at the μ-opioid receptor by
GSK1521498 may have therapeutic potential by decreas-
ing drug stimulus-maintained cocaine and, unlike naltrex-
one, heroin seeking, having the additional effect of
diminishing the impact of an acute relapse, or “lapse”
to heroin taking, thereby promoting abstinence.
Materials and methods
Animals
Seventy four adult male Lister Hooded rats (Charles River,
Margate, UK) weighing 300–320 g at the beginning of the
experiments were individually housed under a reversed
12-h light/dark cycle (lights off at 7:00AM). After a week
of habituation to the animal facility where food and
water were available ad libitum, rats were maintained
on a diet of 20 g of lab chow (Purina) per day given at
the end of each daily experimental session. Experiments
were performed between 9AM and 5PM, 6–7 days a
week, and were conducted in accordance with the UK
(1986) Animal (Scientific Procedures) Act (Project li-
cense 80/2234) and the GSK Policy on the Care,
Welfare and Treatment of Laboratory Animals.
Apparatus
Behavioral training was conducted in operant chambers
(Med Associates, St. Albans, VT, USA) enclosed within a
sound-attenuating box containing a fan to eliminate extra-
neous background noise. Each chamber was equipped with
two retractable levers (4 cm wide, 12 cm apart, and 8 cm
from the grid floor), a cue light (2.5 W, 24 V) above each
lever, and a white house light (2.5 W, 24 V) at the back of
the chamber, in front of the levers. Silastic tubing shielded
with a metal spring extended from each animal’s IV catheter
to a liquid swivel (Stoelting, Wood Dale, IL, USA) mounted
on an arm fixed outside of the operant chamber. Tygon
tubing extended from the swivel to a Razel infusion pump
(Semat Technical, Herts, UK) located adjacent to the exter-
nal chamber. Lever presses, the light stimulus presentation,
the reward delivery, and data collection were controlled by a
PC running Whisker control software (Cardinal and Aitken,
http://www.whiskercontrol.com).
Surgery
Rats were anesthetized with ketamine hydrochloride
(100 mg/kg, IM; Ketaset) and xylazine (9 mg/kg, IM;
Rompun) and implanted with a single catheter in the right
jugular vein. Catheters were made from 22-gauge stainless
steel cannulae attached to Silastic tubing (0.012 ID) and
fixed to nylon mesh, which was sutured subcutaneously
(SC) between the scapulae. Rats were injected SC from
the day before to 7 days post-surgery with the antibiotic
10 mg/kg Baytril (Bayer, Wuppertal, Germany).
Procedure
Daily experimental testing began 7–10 days after intrave-
nous surgery. On each testing day, rats were connected to the
IV line before starting the training session. Active and
inactive levers were counterbalanced between left and right
sides for individual animals. The first step of the training
was a fixed ratio 1 (FR1) schedule of reinforcement: rats
were trained to self-administer cocaine (0.25 mg/infusion)
or heroin (0.04 mg/infusion) by pressing a lever. Each lever
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press resulted in illumination of a light stimulus (condi-
tioned stimulus, CS) above the active lever for 20 s, retrac-
tion of both levers, and extinction of the house light for 20 s
(time out, TO). After this TO, the house light was again
illuminated, the CS was extinguished, and the levers were
again inserted into the chamber. The responses on the inac-
tive lever had no programmed consequences. Rats were
limited to maximum of 30 infusions during each 2-
h session. Following the acquisition of cocaine or heroin
self-administration (3–5 days), a fixed interval (FI) schedule
of reinforcement was introduced as the second step of the
training. The FI increased daily from 1 to 2, 4, 8, and
10 min, before stabilizing at FI15 for three consecutive
sessions. Subsequently, a second-order schedule of rein-
forcement was introduced, in which every tenth active lever
press resulted in a short 1-s CS presentation [FI15(FR10:S)].
This brief CS presentation is optimal for its effect as a
conditioned reinforcer (Everitt and Robbins 2000). At the
tenth active lever press after the FI15 had elapsed, cocaine
or heroin was infused, and the CS was presented for 20 s,
i.e., immediately prior to, during, and immediately after the
infusion. Sessions terminated after either five infusions or
2 h, whichever criterion was met first.
Drugs
GSK1521498 was supplied by GlaxoSmithKline (Harlow,
UK) in an aqueous stock solution of 4 mg/ml, expressed in
terms of the free base, in an acidified hydroxypropyl beta-
cyclodextrin-containing vehicle. Prior to administration, the
stock solution was diluted with a phosphate buffer to yield 1
or 0.1 mg/ml solutions and filtered through a 0.22-micron
filter. The formulation components have been optimized to
yield a final solution pH of 5.2–6.5 and osmolality of
∼290 mOsm/kg. The vehicle solution, the composition of
which was identical to the GSK1521498 stock solution save
for omission of the drug substance, was also supplied by
GlaxoSmithKline (Harlow, UK) and diluted with phosphate
buffer.
NTX (Sigma, UK) was dissolved in sterile physio-
logical saline to yield 3, 1, or 0.1 mg/ml solutions.
NTX doses were selected in order to have the greatest
selectivity for μ-opioid receptors. At higher doses (i.e.,
10 mg/kg), this μ selectivity is lost in favor of in-
creased antagonist potency at δ-opioid receptors
(Stromberg et al. 1998). Moreover, the most effective
and faster subcutaneous route of administration of NTX
was selected in order optimally to compare its effects
with those of GSK1521498. NTX injected subcutane-
ously is 30-fold more potent than when injected intra-
peritoneally (e.g., in reducing ethanol self-administration
in rats) (Williams and Broadbridge 2009). GSK1521498
doses, pre-testing time, and administration route were
based on previous studies (Giuliano et al. 2012; Ignar
et al. 2011); the low solubility of the molecule in water
resulting in its formulation in a cyclodextrin vehicle
makes it unsuitable for subcutaneous injection.
All the solutions were prepared freshly on each test day,
and in all studies, the different doses used were administered
in a counterbalanced order following a Latin square design.
Two or 3 days of washout and re-baselining of behavior
were given between each treatment. Independent cohorts of
rats were used to study GSK1521498 or NTX effects.
Experiments 1A–1B and 2A–2B: effect of GSK1521498
and NTX on cocaine or heroin seeking
Rats were trained to self-administer cocaine (n012 for
GSK1521498 and n017 for NTX) or heroin (n019 for
GSK1521498 and n011 for NTX) under a second-order
schedule of reinforcement. Following extensive second-
order training (>1 month), animals were treated with
GSK1521498 (IP) or NTX (SC) 0, 0.1, 1, and 3 mg/kg, 30
and 10 min before test, respectively.
Experiments 3A–3B and 4A–4B: effect of GSK1521498
and NTX on cocaine or heroin self-administration
The same rats trained to self-administer cocaine or heroin
under second-order schedule of reinforcement were trained
to respond for cocaine under FR1 (n08 for GSK1521498
and n014 for NTX) and FR10 (n08 for GSK1521498 and
n011 for NTX) or heroin under FR1 (n09 for GSK1521498
and n07 for NTX) and FR10 (n08 for GSK1521498 and
n09 for NTX) schedules of reinforcement. Following stable
responding (after 3–6 sessions), animals were treated with
GSK1521498 (IP) or NTX (SC) 0, 0.1, 1, and 3 mg/kg, 30
and 10 min, before test, respectively. Rats were limited to a
maximum of 30 infusions during each 1-hour session, dur-
ing both training and test sessions.
Statistical analyses
For the cocaine- and heroin-seeking experiments, active and
inactive lever responses during the first (pre-drug infusion)
and second (post-drug infusion) 15-min intervals were ana-
lyzed using repeated measures analysis of variance (SPSS
19 and SAS 9.2) with dose as the within-subjects factor.
For the cocaine and heroin self-administration experi-
ments, the number of infusions per session was ana-
lysed. For all analyses following confirmation of
significant main effects, differences between individual
treatments compared to control were analysed using the
Dunnett’s post hoc test. Statistical significance was set
at p<0.05.
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In addition, a second analysis was performed to understand
and compare these changes, and investigate differences in
ratio of behavioral effects between the GSK1521498- and
NTX-treated groups. This random effect analysis, which
reported proportional changes, was computed on a log scale.
Results
Experiment 1A: effects of GSK1521498 on cocaine seeking
Twelve rats acquired responding for cocaine under a second-
order schedule, making ∼300 responses during the first,
drug-free 15-min interval. One animal was excluded from
the analysis due to ill health. Treatment with GSK1521498
resulted in a significant dose-dependent decrease in
responding during the first (pre-cocaine infusion) 15-min
interval of the session [F(3,30)08.9; p<0.001]. This effect
was specific to the active lever since inactive lever respond-
ing was unaffected [F<1]. However, GSK1521498 had no
effect on active lever presses during the second interval
(post-cocaine infusion) [F<1]. Post hoc analysis revealed a
significant effect of GSK1521498 0.1, 1, and 3 mg/kg
during the first interval of the session (p<0.05 for each
dose) (Fig. 1).
Experiment 1B: effects of NTX on cocaine seeking
Twenty animals acquired lever pressing for cocaine un-
der the second-order schedule making ∼300 responses in
15 min for the first cocaine infusion. Three animals
were excluded from further analysis because of catheter
failure. Treatment with NTX resulted in a significant
dose-dependent decrease in seeking responses during
the first (pre-cocaine infusion) 15-min interval of the
session [F(3,48)011.2; p<0.001] but had no effect in
the second interval after cocaine had been self-
administrated [F<1]. Post hoc analysis revealed the first
interval decrease in responding to be significant at 0.1,
1, and 3 mg/kg (p<0.01 for each dose). There were no
significant effects of NTX on inactive lever responding
[first and second intervals: F<1] (Fig. 2).
Comparison between GSK1521498 and NTX effects
on cocaine seeking
Comparing the relative effect of GSK1521498 over NTX
on cocaine seeking, there was a statistically significant,
2.55-fold greater reduction of active lever pressing in the
first 15-min interval following GSK1521498 3 mg/kg
compared to NTX 3 mg/kg (p00.041). Similar but sta-
tistically non-significant effects were seen at lower doses:
1.75- and 1.42-fold greater reductions of active lever
pressing following GSK1521498 compared to NTX at 1
and 0.1 mg/kg, respectively. A graphical summary of
these results, and of the other GSK1521498 to NTX ratio
comparisons, is represented as 95 % confidence intervals
in Fig. 6.
Experiment 2A: effects of GSK1521498 on heroin seeking
Twenty rats acquired responding for heroin under a second-
order schedule, making ∼250 responses during the 15 min
before the first heroin infusion. One animal was excluded
from the analysis due to catheter failure.
Treatment with GSK1521498 resulted in a significant,
dose-dependent decrease in responding during the first
(pre-heroin infusion) 15-min interval of the session [F
Fig. 1 Effects of GSK1521498
on cocaine seeking under a
second-order schedule of
reinforcement during the first
drug-free interval (a, b) and
after cocaine infusion (second
interval) (c, d). Data shown are
mean (+SEM) number of
presses on the active (a, c) and
inactive lever (b, d). Single
asterisk (*) p<.05 compared
with vehicle treated animals
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(3,54)018.82; p<0.001], an effect that was specific to
the active lever since inactive lever responding was un-
affected [F<1]. GSK1521498 also reduced responding
during the second interval (post-heroin infusion) [F
(3,54)012.44; p<0.001]. Post hoc analysis revealed sig-
nificant decreases in first interval responding at the 0.1
(p<0.01), 1 (p<0.001), and 3 mg/kg (p<0.001) doses of
GSK1521498, an increase in second interval responding
at 0.1 mg/kg (p<0.01) and a decrease in second interval
responding at 3 mg/kg (p<0.05) doses (Fig. 3).
Experiment 2B: effects of NTX on heroin seeking
Eleven rats acquired responding for heroin under a
second-order schedule, making ∼290 responses in
15 min for the first infusion of heroin. Treatment with
NTX had no effect on responding during the first [F<1]
or the second [F<1] intervals, i.e., neither before nor
after heroin infusion (Fig. 4).
Comparison between GSK1521498 and NTX effects
on heroin seeking
Compared to NTX, GSK1521498 caused a greater reduction
in response under all testing conditions except following the
lowest dose in the second interval. Furthermore, for all but
the lowest dose, these effects were statistically significant at
the 5 % level. Dose-dependent fold change reductions in
heroin-seeking behavior following GSK1521498 compared
to NTX were estimated as 1.66 (0.1 mg/kg), 4.53 (1 mg/kg),
Fig. 2 Effects of naltrexone on
cocaine seeking under a
second-order schedule of
reinforcement during the first
drug-free interval (a, b) and
after cocaine infusion (second
interval) (c, d). Data shown are
mean (+SEM) number of
presses on the active (a, c) and
inactive lever (b, d). Double
asterisk (**) p<.01 compared
with vehicle treated animals
Fig. 3 Effects of GSK1521498
on heroin seeking under a
second-order schedule of
reinforcement during the first
drug-free interval (a, b) and
after heroin infusion (second
interval) (c, d). Data shown are
mean (±SEM) number of
presses on the active (a, c) and
inactive lever (b, d). Single
asterisk (*) p<.05, double
asterisk (**) p<.01, and triple
asterisk (***) p<.001
compared with vehicle treated
animals
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and 5.50 (3 mg/kg) for the first interval and 2.43 (1 mg/kg)
and 3.02 (3 mg/kg) for the second interval (Fig. 6).
Experiments 3A–3B: effects of GSK1521498 and NTX
on cocaine self-administration
GSK1521498 and NTX had no effect on cocaine self-
administration under either FR1 or FR10 schedules of
reinforcement [F<1] (Fig. 5).
Experiments 4A–4B: effects of GSK1521498 and NTX
on heroin self-administration
GSK1521498 0.1, 1, and 3 mg/kg increased the number of
heroin infusions [F(3,24)09.9; p00.001] under FR1 schedule
of reinforcement (p<0.01 for each dose).When the schedule of
reinforcement was increased to FR10, GSK1521498 1 mg/kg
similarly increased the number of infusions earned per session
(p<0.001) (Fig. 5).
Treatment with NTX 0.1, 1, and 3 mg/kg resulted in
an increased number of heroin infusions [F(3,18)024.4;
p<0.001] under a FR1 schedule of reinforcement (p<
0.001 for each dose). When the schedule of reinforce-
ment was increased to FR10, NTX 1 mg/kg similarly
increased the number of infusions earned per session
(p<0.001) (Fig. 5).
There were no significant differences between
GSK1521498 and NTX in their effects on heroin or
cocaine self-administration (Fig. 6).
Discussion
The present study shows that selective antagonism at the μ-
opioid receptor by the novel compound GSK1521498
markedly reduced both cocaine and heroin seeking in
comparison to NTX, which had no effect on heroin
seeking and a significantly lesser effect on cocaine
seeking. In addition, GSK1521498 also decreased hero-
in, but not cocaine, seeking after the first drug infusion
had been self-administered. Neither GSK1521498 nor
NTX had any effect on the self-administration of co-
caine, i.e., they did not alter the primary reinforcing
effects of cocaine but did, as expected, result in an
increase in the self-administration of heroin, confirming
results of earlier studies (Ettenberg et al. 1982).
Opioid neurotransmission, in particular via μ-opioid
receptors, is implicated in regulating food intake and in
mediating the rewarding impact of palatable food (Nathan
and Bullmore 2009), but it has also been suggested to
impact incentive salience attribution to CSs that predict
reward (Peciña 2008), and μ-opioid receptor knockout
mice show a reduced food-anticipatory activity (Kas et
al. 2004). Moreover, μ-opioid receptor agonists infused
into the NAcc increase the motivation to work for highly
palatable food prior to its delivery (Zhang et al. 2003).
Previously, we have shown using a second-order sched-
ule of highly palatable food (chocolate) reinforcement
that GSK1521498, but not NTX, significantly reduced
chocolate seeking as well as binge eating (Giuliano et
al. 2012). In the context of (1) the clinical use of NTX
to decrease alcohol (Volpicelli et al. 1992) and cocaine
(Schmitz et al. 2001) craving and (2) findings suggesting
that opioid receptor signaling mediates conditioned
effects of environmental stimuli associated with drugs
of abuse (Zubieta et al. 2005), we investigated in detail
the effect of GSK1521498 and NTX under conditions in
which drug-associated incentive stimuli are critically im-
portant for maintaining heroin- and cocaine-seeking be-
havior over extended delays to reinforcement.
Fig. 4 Effects of naltrexone on
heroin seeking under a second-
order schedule of reinforcement
during the first drug-free inter-
val (a, b) and after heroin infu-
sion (second interval) (c, d).
Data shown are mean (+SEM)
number of presses on the active
(a, c) and inactive lever (b, d)
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Heroin seeking
The present results confirmed those of our initial study that
also failed to show an effect of naloxone on heroin seeking
(Alderson et al. 2000). However, by the third day of nalox-
one treatment, as the rats presumably learned about the
decreased value of heroin under naloxone (Alderson et al.
2000), responding for heroin decreased, leading to the
Fig. 6 Differential efficacy of GSK1521498 compared to naltrexone
on cocaine and heroin seeking (a) and self-administration behavior (b).
Each vertical line in the plot is a 95 % confidence interval for the fold
difference in effect of GSK1521498 versus NTX at each of three doses
(0.1, 1, and 3 mg/kg) in log scale. Positive values indicate that
GSK1521498 has a greater effect than NTX, causing greater reduction
or fold decrease in cocaine- or heroin-seeking behavior; the horizontal
line highlights a fold difference of 1 or equivalent efficacy of the two
drugs. If a confidence interval does not include 1, that is equivalent to a
statistically significant difference in efficacy of GSK1521498 com-
pared to NTX
Fig. 5 Top: effects of GSK1521498 (a, b) and naltrexone (b, c) on
cocaine self-administration under a fixed-ratio 1 (a, c) and a fixed-ratio
10 (b, d) schedule of reinforcement. Bottom: effects of GSK1521498
(e, f) and naltrexone (g, h) on heroin self-administration under a fixed-
ratio 1 (e, g) and a fixed-ratio 10 (f, h) schedule of reinforcement. Data
shown are mean (+SEM) number of infusions reached per session.
Double asterisk (**) p<.01 and triple asterisk (***) p<.001 compared
with vehicle treated animals
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gradual extinction of heroin-seeking behavior. In the present
study, under identical schedule conditions and acute treat-
ment, GSK1521498, but not NTX, markedly reduced
responding during the first interval of the session and, at
the highest dose, also after the first heroin infusion was
earned. This result suggests that selective inhibition at μ-
opioid receptors is required to reduce cue-induced heroin
seeking, and this does not simply depend on a devaluation
of the effects of heroin by the opiate receptor antagonist. In
addition, GSK1521498 also affected seeking behavior, as
measured by active lever responses after heroin had been
self-administered, increasing responding at the lowest dose
and markedly decreasing it at the highest dose. This post-
heroin infusion inverted U-shaped dose–response function
likely reflects, successively, the reduced and then more
completely antagonized reinforcing effects of the drug by
GSK1521498. When GSK1521498 and NTXwere given prior
to a heroin self-administration session under the less demand-
ing continuous or FR10 reinforcement schedules, both as
expected increased the number of infusions in 1-hour sessions
in a dose-dependent manner, i.e., the animals responded to
increasing doses of the antagonist by increasing their intake
of heroin (Ettenberg et al. 1982). However, the maximum
number of 30 infusions allowed in each 1-hour session may
have precluded a clear dose–response distinction between the
doses of 1 and 3 mg/kg, for both GSK1521498 and NTX.
Previous studies have clearly demonstrated the effect of inhib-
iting opioid receptor signaling to reduce heroin-induced
(Shaham and Stewart 1996) and intra-VTA morphine-induced
(Stewart 1984) reinstatement of responding after extinction, as
well as to reduce responding to heroin-paired cues (Sorge et al.
2005). However, these procedures, based on instrumental
extinction and reinstatement, do not readily allow distinctions
to be made between the effects of μ-opioid receptor antagonists
on extinction learning (Peters et al. 2008) versus cued mecha-
nisms of relapse. The present data strongly indicate an effect on
the conditioned control over heroin seeking.
Cocaine seeking
The results described in the present study further
showed that GSK1521498 reduced cocaine seeking and
that it did so significantly more effectively than NTX.
The effects of both compounds were in this case spe-
cific to cocaine seeking since there was no effect on
responding after the cocaine infusion had been deliv-
ered. Moreover, neither GSK1521498 nor NTX altered
the self-administration of cocaine under a simple fixed
ratio schedule, indicating modulation of mechanisms
regulating cocaine-seeking behavior rather than cocaine
reinforcement. Previous studies have suggested that the
mixed μ-opioid receptor agonist–antagonist buprenor-
phine and NTX might be useful in treating cocaine
dependence. Buprenorphine has been reported effectively
to reduce cocaine and opioid self-administration in both
humans (Kosten et al. 1989) and laboratory animals (Mello
et al. 1990; Carroll and Lac 1992), and NTXwas also effective
in suppressing cocaine and heroin self-administration in
humans (Kosten et al. 1989) and monkeys (Mello et al.
1990). However, the effects of NTX in rats are less consistent,
having been reported to increase (Carroll et al. 1986), to
decrease (Corrigall and Coen 1991), or, as reported here, to
have no effect on cocaine self-administration (Ettenberg et al.
1982). Acute NTX treatment also had no effect on cocaine-
induced reinstatement of responding (Comer et al. 1993),
whereas the sub-chronic pre-treatment progressively attenuat-
ed cocaine-induced reinstatement of extinguished responding
(Gerrits et al. 2005). NTX has been reported to diminish
cocaine seeking induced by re-exposure to cocaine-
associated cues after extinction (Burattini et al. 2008), an
effect consistent with that reported here, that was itself less
pronounced than the effect of GSK1521498.
The apparently greater efficacy of GSK1521498 com-
pared to NTX in reducing cocaine, and especially heroin,
seeking may reflect different opioid receptor subtype selec-
tivities. GSK1521498 is 14- and 20-fold selective for human
μ- over κ- and δ-opioid receptors and is 52- and 66-fold
selective for rat μ- over κ- and δ-opioid receptors, whereas
NTX is 4- and 10-fold selective at human μ- versus κ- and
δ-opioid receptors and 20- and 25-fold selective at rat μ-
compared with κ- and δ-opioid receptors (Ignar et al. 2011).
The mean exposures achieved following a 3-mg/kg dose of
GSK1521498 in mice and rats are broadly similar: AUC
(0–∞) and Cmax of 5,254.6 and 887.9 ng/ml for mice,
compared to 9,159.1 and 1,082.7 ng.h/ml for rats. Thus, it
seems reasonable to assume that equivalent doses of
GSK1521498 translate into approximately equivalent plas-
ma concentrations in both rat and mouse. Based on the μ-
opioid receptor occupancy of GSK1521498 and NTX mea-
sured in mice, GSK1521498 and NTX dose-dependently
and completely occupied brain μ-opioid receptors in adult
male C57BL/6J mice. The dose achieving 50 % occupancy
(OD50) in mice ranged from 0.041 to 0.064 mg/kg for NTX
(SC administration). The OD50 for GSK1521498 ranged
from 1.24 to 2.23 mg/kg (IP administration). Consistent
with estimated OD50 values, NTX achieved greater MOR
occupancy at all dose levels than that achieved by
GSK1521498. In mice, equivalent doses up to 3 mg/kg
NTX (SC) or GSK1521498 (IP) achieved receptor occupan-
cy of 93–94 % for NTX and 64–73 % for GSK1521498 in
the nucleus accumbens and caudate putamen, respectively.
While obvious caveats apply in translating μ-opioid recep-
tor occupancy data from mouse to rat, they indicate that
NTX achieves greater receptor occupancy than
GSK1521498 at equivalent doses. The superior efficacy of
GSK1521498 demonstrated behaviorally by these
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experiments is therefore not readily attributable to its greater
receptor occupancy compared to NTX at equivalent doses.
A more likely explanation follows from the prior observa-
tion that NTX has partial agonist activity (about 20 % of
maximum agonist activity) at the μ-opioid receptor, whereas
GSK1521498 has no partial agonist activity and is therefore
more completely effective in blocking activation of the
receptor by an agonist in cellular assays (Ignar et al. 2011).
Thus, a given dose of GSK1521498 putatively has greater
effect on μ-opioid receptor agonist-driven behavior than an
equivalent dose of NTX not because it achieves greater recep-
tor occupancy but because it has greater net antagonistic
activity at the receptor.
Neurobiological mechanisms of cocaine and heroin seeking
The common effect of GSK1521498 to reduce cocaine and
heroin seeking, as well as the seeking of highly palatable food
(Giuliano et al. 2012), may reflect actions on a common neural
mechanism for incentive motivation. Acquisition and/or per-
formance of drug seeking under second-order schedules of
reinforcement or the reinstatement of seeking responses de-
pend upon the nucleus accumbens core and its afferents from
the basolateral amygdala (Vanderschuren et al. 2005), as well
as dopaminergic activity in the dorsal striatum, when previ-
ously well established (Belin and Everitt 2008). Drug-seeking
behavior is potentiated by drug-induced increases in DA
release (Arroyo et al. 1998) and can be reduced by
GABAergic inhibition of VTA dopaminergic neurons (Di
Ciano and Everitt 2004). One possible locus of the effect of
GSK1521498 and NTX to reduce heroin and cocaine seeking
may be via blockade of μ-opioid receptors on VTA
GABAergic interneurons, thereby increasing GABAergic
and decreasing mesolimbic DAergic transmission. Actions
within the nucleus accumbens (Di Ciano et al. 2003) or globus
pallidus (Smith et al. 2009) to reduce the incentive value of
reward-associated CSs (Flagel et al. 2011), each of which can
modulate incentive or hedonic motivational responses, are
alternative or additional sites of action. The marked effect of
GSK1521498 and NTX to reduce cocaine and heroin seeking
under second-order schedules of drug reinforcement suggests
diminished control over the high levels of responding main-
tained by drug-associated conditioned stimuli.
Clinical implications
Although NTX is in use clinically both to reduce alcohol
craving (Volpicelli et al. 1992) and alcohol intake (Davidson
et al. 1999) and in exploratory clinical studies to reduce
amphetamine craving (Jayaram-Lindström et al. 2008), the
considerable individual differences in response to the drug,
perhaps due to its short half-life and mixed antagonist and
partial agonist profile, can result in poor medication
compliance (McCaul et al. 2000). Moreover, NTX under-
goes first-pass metabolism in the liver to form its major, but
less active, metabolite 6-β-naltrexol, high urinary levels of
which have been found in subjects who experience adverse
side effects (King et al. 1997). Although some of the dis-
advantages of NTX, especially its short half-life, may be
avoided using an extended-release injectable form
(Vivitrol®), other unwanted effects, such as adverse injec-
tion site reactions, have been reported, while its partial
agonist effects remain.
Treatment of volunteers with GSK1521498 has demon-
strated a longer plasma half-life of the drug and much less
first-pass metabolism than NTX. Additionally, GSK1521498
significantly attenuated activation of amygdala and ventral
striatum by food-associated stimuli in a functional imaging
study, whereas NTX did not (Rabiner et al. 2011). Taken
together with the results reported here, we suggest that
GSK1521498, with its full μ-opioid receptor antagonist pro-
file, may be more effective therapeutically than NTX, espe-
cially in the promotion of abstinence and in the prevention of
cocaine and heroin relapse in addicted individuals seeking
treatment. Moreover, its unique effect to reduce heroin seek-
ing even after self-administration of an infusion of heroin may
indicate its potential use to prevent full or sustained relapse
after an initial lapse to heroin taking. These and other behav-
ioral data on binge eating and food seeking (Giuliano et al.
2012) suggest that GSK1521498 can generally attenuate
reward-driven or reward-seeking behaviors, whether these
are incentivised by chocolate, cocaine, or heroin. This cross-
cutting efficacy on multiple species of reward-seeking behav-
ior in animal models suggests that GSK1521498 could have
therapeutic efficacy in several clinical disorders characterized
by compulsive consumption of rewards. It also potentially
raises a risk for clinical development, namely that attenuation
of abnormal, compulsive reward-seeking behavior might also
attenuate the capacity for more normal responsivity to reward-
ing stimuli. However, recent clinical data from a study of
GSK1521498 in patients with binge eating and obesity, trea-
ted for 28 days at doses of 2 and 5 mg/day, demonstrated no
evidence for adverse effects of GSK1521498 on measures of
mood or the capacity for pleasurable responses to sexual or
other normal rewards (Ziauddeen et al. 2012).
These therapeutic predictions, based largely on the results
of our pre-clinical behavioral experiments, merit further in-
vestigation in translational studies of GSK1521498 for the
treatment of patients with substance dependence disorders.
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